HENLIUS (02696) announced that on February 24, 2026, following friendly negotiations, the company entered into an amendment and partial termination agreement with KGBio. This agreement terminates the exclusive licensing rights for the licensed product in regions outside of Indonesia under the original KGBio license agreement. On the same day, the company entered into an amendment to the license agreement with Abbott, revising certain terms related to the licensed territories and milestone payments for the licensed product under the original Abbott agreement. The revisions are intended to further expand the licensed territories for the product to include the regions terminated with KGBio and other specified countries or areas. After friendly discussions, HENLIUS and KGBio have ended their commercialization collaboration for the licensed product in the terminated regions. The exclusive commercialization rights for the product in the newly added territories have been granted to Abbott. Previously, HENLIUS has established a strong cooperative relationship with Abbott for the commercialization of several products in numerous regions globally. This expansion of the collaboration with Abbott for the licensed product in the new territories is expected to better facilitate the product's expansion into overseas markets and enhance its accessibility and recognition in the international market.